Surveillance of Humira Injection in Korean Patients
Launched by ABBVIE (PRIOR SPONSOR, ABBOTT) · Mar 8, 2010
Trial Information
Current as of May 18, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- * Adult patients (19 years and above) with one of the following indications:
- • Moderately to severely active rheumatoid arthritis or
- • active and progressive psoriatic arthritis when the response to previous disease-modifying anti-rheumatic drug therapy has been inadequate or
- • severe active ankylosing spondylitis who have had an inadequate response to conventional therapy or
- • severely active Crohn's disease who have had no response, intolerance or contraindication to corticosteroid therapy or immunosuppressants or
- • moderately to severely active psoriasis patients who have had no response, have intolerance or have contraindication to systemic therapies including cyclosporine, methotrexate or photochemotherapy (PUVA).
- • Patients who give verbal or written authorization to use their personal and health data.
- Exclusion Criteria:
- • - Patients with known hypersensitivity to adalimumab or any of its excipients.
About Abbvie (Prior Sponsor, Abbott)
AbbVie is a global biopharmaceutical company formed in 2013 as a spinoff from Abbott Laboratories, focusing on the discovery, development, and commercialization of advanced therapies for complex diseases. With a commitment to innovation and patient-centric solutions, AbbVie leverages cutting-edge research and a robust pipeline to address unmet medical needs across various therapeutic areas, including immunology, oncology, and neuroscience. The company's dedication to advancing healthcare is underscored by its collaborative approach, engaging with healthcare professionals, patients, and stakeholders to deliver groundbreaking treatments that improve patient outcomes and quality of life.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Ansan, , Korea, Republic Of
Ansan, , Korea, Republic Of
Bucheon, , Korea, Republic Of
Bucheon, , Korea, Republic Of
Busan, , Korea, Republic Of
Busan, , Korea, Republic Of
Busan, , Korea, Republic Of
Busan, , Korea, Republic Of
Cheonan, , Korea, Republic Of
Cheonan, , Korea, Republic Of
Daegu, , Korea, Republic Of
Daegu, , Korea, Republic Of
Daegu, , Korea, Republic Of
Daegu, , Korea, Republic Of
Daejeon, , Korea, Republic Of
Daejeon, , Korea, Republic Of
Daejeon, , Korea, Republic Of
Daejeon, , Korea, Republic Of
Goyang, , Korea, Republic Of
Guri, , Korea, Republic Of
Guri, , Korea, Republic Of
Gwangju, , Korea, Republic Of
Gwangju, , Korea, Republic Of
Gwangju, , Korea, Republic Of
Gwangju, , Korea, Republic Of
Gwangju, , Korea, Republic Of
Gyeongju, , Korea, Republic Of
Iksan, , Korea, Republic Of
Incheon, , Korea, Republic Of
Jeju, , Korea, Republic Of
Jeju, , Korea, Republic Of
Jeollabuk Do, , Korea, Republic Of
Jeonju, , Korea, Republic Of
Jinju, , Korea, Republic Of
Masan, , Korea, Republic Of
Metropolitan City Daejon, , Korea, Republic Of
Pohang, , Korea, Republic Of
Seongnam, , Korea, Republic Of
Seongnam, , Korea, Republic Of
Seoul, , Korea, Republic Of
Seoul, , Korea, Republic Of
Seoul, , Korea, Republic Of
Seoul, , Korea, Republic Of
Seoul, , Korea, Republic Of
Seoul, , Korea, Republic Of
Seoul, , Korea, Republic Of
Seoul, , Korea, Republic Of
Seoul, , Korea, Republic Of
Seoul, , Korea, Republic Of
Seoul, , Korea, Republic Of
Seoul, , Korea, Republic Of
Seoul, , Korea, Republic Of
Seoul, , Korea, Republic Of
Seoul, , Korea, Republic Of
Seoul, , Korea, Republic Of
Seoul, , Korea, Republic Of
Seoul, , Korea, Republic Of
Seoul, , Korea, Republic Of
Seoul, , Korea, Republic Of
Seoul, , Korea, Republic Of
Seoul, , Korea, Republic Of
Seoul, , Korea, Republic Of
Seoul, , Korea, Republic Of
Seoul, , Korea, Republic Of
Seoul, , Korea, Republic Of
Seoul, , Korea, Republic Of
Seoul, , Korea, Republic Of
Seoul, , Korea, Republic Of
Seoul, , Korea, Republic Of
Seoul, , Korea, Republic Of
Suwon Si, , Korea, Republic Of
Suwon, , Korea, Republic Of
Taegu, , Korea, Republic Of
Uljeongbu, , Korea, Republic Of
Ulsan, , Korea, Republic Of
Ulsan, , Korea, Republic Of
Wonju, , Korea, Republic Of
Patients applied
Trial Officials
Deborah Chee, MD
Study Director
AbbVie Ltd.
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials